Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS SEC filings (Ticker: SHPH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Shuttle Pharmaceuticals Holdings, Inc. files regulatory reports that document its clinical-stage pharmaceutical business, Molecule.ai software platform, capital structure and governance. Registration statements and related amendments describe securities offered by the company, risk factors, use-of-proceeds disclosures and security terms, including common stock and pre-funded warrant structures.
Its 8-K reports record material agreements, public-offering activity, preliminary operating results and executive or consulting arrangements. Proxy materials cover annual meeting matters such as director elections, auditor ratification, executive-compensation votes and charter-authority proposals.
Shuttle Pharmaceuticals Holdings, Inc. is offering 2,238,800 shares of common stock and pre-funded warrants to purchase up to 4,761,200 shares of common stock at $0.50 per share and $0.499 per pre-funded warrant, respectively.
The pre-funded warrants are immediately exercisable for $0.001 per share and will not be listed. The offering is being placed on a "best efforts" basis by E.F. Hutton & Co., with expected delivery on or about March 9, 2026. Net proceeds are estimated at approximately $3.04 million, of which up to $1.5 million is intended for marketing and the remainder for working capital and general corporate purposes.
The company completed an asset acquisition of Molecule.ai on November 20, 2025 and committed to discontinue its clinical trials of Ropidoxuridine on November 20, 2025. Preliminary unaudited 2025 results show an expected net loss between $(10.9) million and $(12.1) million; cash and current assets and certain liabilities are presented with working capital deficit expectations as of December 31, 2025.
Shuttle Pharmaceuticals Holdings, Inc. furnished preliminary, unaudited results for the year ended December 31, 2025, showing no revenue and an estimated net loss between $10.9 million and $12.1 million, compared with an actual net loss of $9.1 million in 2024.
Total operating expenses for 2025 are expected between $10.7 million and $11.9 million, up from $7.7 million, driven mainly by a jump in general and administrative costs to an estimated $5.2 million–$5.8 million versus $1.4 million in 2024, largely due to $3.6 million of investor relations advertising.
Research and development spending is projected in a narrow range around the prior year’s $3.6 million, while legal and professional expenses are expected to decline slightly from $2.7 million. As of December 31, 2025, the company anticipates current assets of about $0.5 million and current liabilities of $1.2 million–$1.3 million, implying a working capital deficit of $0.7 million–$0.8 million, compared with positive working capital of $0.7 million a year earlier.
Shuttle Pharmaceuticals Holdings, Inc. is registering up to 2,229,300 shares of common stock and pre-funded warrants to purchase up to 2,229,300 shares in a best efforts public offering. The assumed public offering price is $1.57 per share or pre-funded warrant, implying up to $3.5 million in gross proceeds and estimated net proceeds of about $3.03 million if fully sold.
The company plans to use up to $1.5 million for future marketing, including a new agreement with IR Agency LLC, and the balance for working capital and general corporate purposes. Shuttle recently acquired the AI-driven Molecule.ai platform and discontinued clinical trials of its lead drug candidate, and it preliminarily estimates a 2025 net loss between $10.9 million and $12.1 million with no revenue.
Shuttle Pharmaceuticals Holdings, Inc. has filed an S-1 to offer up to 2,229,300 shares of common stock, or pre-funded warrants in lieu of shares, plus the common shares underlying those pre-funded warrants. The assumed price is $1.57 per share, matching the February 5, 2026 Nasdaq close.
The company recently acquired the Molecule.ai AI drug-discovery platform and has discontinued clinical trials of its lead drug candidate, Ropidoxuridine, signaling a shift toward AI-driven discovery. Preliminary 2025 results show no revenue and a higher net loss of $10.9–$12.1 million versus $9.1 million in 2024, driven largely by a jump in general and administrative expenses tied to $3.6 million of investor-relations advertising.
As of December 31, 2025, Shuttle expects a working capital deficit of $0.7–$0.8 million and $9.8 million of intangible assets from the Molecule.ai acquisition, with $6.4 million of contingent and payable consideration remaining. Net proceeds from this offering are estimated at about $3.03 million, with $1.5 million earmarked for marketing and the balance for working capital and general corporate purposes.
Shuttle Pharmaceuticals Holdings, Inc. amended its consulting agreement with Number 2 Capital Corp., the entity owned by interim co-Chief Executive Officer Christopher Cooper. The amendment, dated January 29, 2026, extends the agreement’s term to August 1, 2026, effective September 11, 2025.
Under the agreement, the consultant is paid $20,000 per month, is expected to work 40 hours per week, and is subject to standard confidentiality and non-disclosure provisions. Either party may terminate the agreement on 30 days’ notice, or immediately for cause.
Shuttle Pharmaceuticals Holdings, Inc. has filed a resale prospectus covering 625,156 shares of common stock issuable upon exercise of a pre-funded warrant held by a single selling stockholder. The warrant has a nominal exercise price of $0.001 per share and no expiration, with a 4.99% beneficial ownership cap.
The warrant was issued in a November 2025 private placement that generated approximately $2.5 million in gross proceeds for Shuttle; the company will receive no proceeds from the resale of these registered shares. A prior June 2025 private placement with the same investor raised about $4.3 million.
Shuttle is pivoting its business by acquiring substantially all assets and liabilities of Molecule.ai, an AI-driven molecular discovery platform, while discontinuing clinical trials of its lead candidate Ropidoxuridine. Incorporated financial statements include an auditor paragraph raising substantial doubt about the company’s ability to continue as a going concern.
Shuttle Pharmaceuticals Holdings, Inc. reported leadership changes. The Board appointed Yuying Liang, CPA as Chief Financial Officer, effective from an engagement under which her firm, Yuying Liang Professional Corp., will provide bookkeeping, accounting, and financial reporting services for a monthly fee of $15,000 plus applicable taxes. Former CFO Chris Cooper will no longer serve as Chief Financial Officer but will continue in his role as Interim Chief Executive Officer.
The company also disclosed that Sachin Pathigoda resigned from the Board of Directors, effective immediately, and stated his resignation was not due to any disagreement with the company’s operations, policies, or practices. The Board has begun a process to identify a new director to fill the vacancy in line with the company’s bylaws and applicable law.
Shuttle Pharmaceuticals Holdings, Inc. Chief Financial Officer Yuying Liang has filed an initial insider ownership report on Form 3. The filing states that no securities of Shuttle Pharmaceuticals are beneficially owned, and both the non-derivative and derivative securities tables contain no holdings. This is a routine disclosure establishing that, as of the event date, the CFO reports no direct or indirect ownership of the company’s stock.
Shuttle Pharmaceuticals Holdings, Inc. disclosed that it entered into a First Amendment to its Asset Purchase Agreement with its Canadian subsidiary, the seller 1542770 BC Ltd., and an individual guarantor on December 23, 2025. Under this amendment, the company accelerated part of the first installment payment by issuing 320,496 shares of common stock on the effective date. These shares were valued at $1.76 per share and represented 19.99% of the issued and outstanding common stock as of the original agreement’s closing date.
The remaining portion of the first installment payment will be paid in cash according to the existing agreement terms. The share issuance was completed on the effective date as an unregistered sale of equity securities, relying on exemptions under Section 4(a)(2), Rule 506(b), and Rule 903 of Regulation S.